By Tony Fong

NEW YORK (GenomeWeb News) – Having demonstrated the utility of its technology, molecular diagnostics firm Sequenta will focus on clinical validation of its technology in 2012 with an expected launch of its first product next year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.